AU2009325950B2 - IgE CH3 peptide vaccine - Google Patents

IgE CH3 peptide vaccine Download PDF

Info

Publication number
AU2009325950B2
AU2009325950B2 AU2009325950A AU2009325950A AU2009325950B2 AU 2009325950 B2 AU2009325950 B2 AU 2009325950B2 AU 2009325950 A AU2009325950 A AU 2009325950A AU 2009325950 A AU2009325950 A AU 2009325950A AU 2009325950 B2 AU2009325950 B2 AU 2009325950B2
Authority
AU
Australia
Prior art keywords
seq
antigenic ige
group
peptide
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009325950A
Other languages
English (en)
Other versions
AU2009325950A1 (en
Inventor
Alan Daniel Brown
Brian Robert Champion
Clare Christy
David Paul Gervais
Lyn Howard Jones
Anne Maria Kristina Kjerrstrom
David Cameron Pryde
Lee Richard Roberts
David Michael Wyatt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Vaccines LLC
Original Assignee
Pfizer Vaccines LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42035836&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2009325950(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Vaccines LLC filed Critical Pfizer Vaccines LLC
Publication of AU2009325950A1 publication Critical patent/AU2009325950A1/en
Application granted granted Critical
Publication of AU2009325950B2 publication Critical patent/AU2009325950B2/en
Priority to AU2013204233A priority Critical patent/AU2013204233B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2009325950A 2008-12-09 2009-12-04 IgE CH3 peptide vaccine Ceased AU2009325950B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013204233A AU2013204233B2 (en) 2008-12-09 2013-04-12 IgE CH3 peptide vaccine

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12098908P 2008-12-09 2008-12-09
US61/120,989 2008-12-09
PCT/IB2009/055508 WO2010067286A2 (en) 2008-12-09 2009-12-04 IgE CH3 PEPTIDE VACCINE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013204233A Division AU2013204233B2 (en) 2008-12-09 2013-04-12 IgE CH3 peptide vaccine

Publications (2)

Publication Number Publication Date
AU2009325950A1 AU2009325950A1 (en) 2010-06-17
AU2009325950B2 true AU2009325950B2 (en) 2013-03-07

Family

ID=42035836

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009325950A Ceased AU2009325950B2 (en) 2008-12-09 2009-12-04 IgE CH3 peptide vaccine

Country Status (21)

Country Link
US (3) US8298547B2 (https=)
EP (2) EP2865389A1 (https=)
JP (4) JP5209800B2 (https=)
KR (3) KR101413844B1 (https=)
CN (1) CN102245198B (https=)
AR (1) AR074505A1 (https=)
AU (1) AU2009325950B2 (https=)
BR (1) BRPI0922561A2 (https=)
CA (1) CA2744754A1 (https=)
CO (1) CO6561830A2 (https=)
DK (1) DK2376108T3 (https=)
ES (1) ES2622562T3 (https=)
IL (1) IL213029A0 (https=)
MX (2) MX2011006077A (https=)
NZ (2) NZ604186A (https=)
PE (2) PE20142330A1 (https=)
RU (1) RU2495049C2 (https=)
SG (2) SG186611A1 (https=)
TW (1) TWI387463B (https=)
WO (1) WO2010067286A2 (https=)
ZA (1) ZA201104072B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2618796C (en) * 2005-08-11 2018-01-02 Arpi Matossian-Rogers Peptides for treatment and diagnosis of autoimmune disease
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
HUE027823T2 (hu) 2008-12-09 2016-11-28 Coley Pharm Group Inc Immunstimuláló oligonukleotidok
EP2575868A1 (en) * 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
EP2471926A3 (en) 2010-12-30 2012-07-11 Intervet International BV Immunostimulatory oligodeoxynucleotides
US9359602B2 (en) * 2011-05-26 2016-06-07 Intervet Inc. Immunostimulatory oligodeoxynucleotides
CN103547675A (zh) 2011-05-26 2014-01-29 英特维特国际股份有限公司 免疫刺激性寡脱氧核苷酸
WO2013110030A2 (en) 2012-01-19 2013-07-25 Duke University Vaccines against antigens involved in therapy resistance and methods of using same
US9187553B2 (en) * 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
CN104395337A (zh) * 2012-06-18 2015-03-04 日本全药工业株式会社 IgE肽疫苗
US20170196953A1 (en) 2014-07-07 2017-07-13 Duke University VACCINES AGAINST AN ONCOGENIC ISOFORM OF HER2 (ErbB2) AND METHODS OF USING THE SAME
EP3166630A4 (en) 2014-07-07 2018-03-28 Duke University Vaccines against an oncogenic isoform of esr1 and methods of using the same
NZ728041A (en) 2014-07-10 2023-01-27 Affiris Ag Substances and methods for the use in prevention and/or treatment in huntington’s disease
WO2018179172A1 (ja) * 2017-03-29 2018-10-04 塩野義製薬株式会社 免疫賦活活性を有する核酸誘導体
KR102230325B1 (ko) * 2015-09-30 2021-03-19 시오노기 앤드 컴파니, 리미티드 면역 부활 활성을 갖는 핵산 유도체
KR101876620B1 (ko) * 2015-10-27 2018-07-09 대구한의대학교산학협력단 펩타이드 기반 분자결합자를 이용한 노로바이러스 검출칩 및 그 제작방법
WO2017120576A1 (en) 2016-01-07 2017-07-13 Duke University Cancer vaccines and methods of delivery
JP7041923B2 (ja) 2016-03-03 2022-03-25 学校法人藤田学園 大豆アレルギーの抗原
US11224665B2 (en) 2016-10-05 2022-01-18 Duke University Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same
US10487143B2 (en) 2016-10-05 2019-11-26 Duke University Vaccines against HER3 antigens and methods of using the same
CN116134138B (zh) * 2020-08-13 2026-04-10 纳米智能生物医学工程有限公司 靶向细胞内诱瘤蛋白的抗体、或其单链可变片段与癌细胞穿透肽的融合蛋白、及其用途
KR20230110249A (ko) 2020-09-17 2023-07-21 니오베크스 IgE-매개 염증성 장애를 치료하기 위한 IgE 단편을 포함하는 면역원성 생성물
WO2023192203A2 (en) * 2022-03-28 2023-10-05 The Regents Of The University Of California Novel plant virus and bacteriophage vaccines

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0263655A2 (en) * 1986-10-03 1988-04-13 Dainippon Pharmaceutical Co., Ltd. Novel peptides having antiallergic activity
WO1999067293A1 (en) * 1998-06-20 1999-12-29 United Biomedical Inc. Peptide composition as immunogen for the treatment of allergy
EP1195161A2 (en) * 2000-08-30 2002-04-10 Pfizer Products Inc. Anti-IgE vaccines
US20030170229A1 (en) * 1999-02-25 2003-09-11 Smithkline Beecham Biologicals S.A. Vaccine
WO2004058799A2 (en) * 2002-12-20 2004-07-15 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of ige to a high affinity receptor

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2055131B (en) 1978-09-29 1982-12-15 Energy Secretary Of State For Electrical power transmission in fluid wells
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
WO1983001451A1 (en) 1981-10-23 1983-04-28 Molecular Biosystems Inc Oligonucleotide therapeutic agent and methods of making same
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
NZ235315A (en) 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US5258289A (en) * 1990-09-05 1993-11-02 Davis Claude G Method for the selecting of genes encoding catalytic antibodies
EP0563091A1 (en) 1990-12-20 1993-10-06 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccines based on hepatitis b surface antigen
SE9102808L (sv) 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
DK0671948T3 (da) 1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
ATE157882T1 (de) 1993-03-23 1997-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
DE4321946A1 (de) 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5658738A (en) 1994-05-31 1997-08-19 Becton Dickinson And Company Bi-directional oligonucleotides that bind thrombin
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ATE509102T1 (de) 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
WO1996030523A2 (en) 1995-03-31 1996-10-03 Hans Wolf Antigen presentation system based on retrovirus-like particles
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
KR100584051B1 (ko) 1996-03-01 2006-05-30 노파르티스 아게 알레르기에 대한 백신 접종 및 치료를 위한 펩티드임뮤노겐
ID18046A (id) 1996-08-20 1998-02-19 Takeda Chemical Industries Ltd Senyawa siklik campuran, pembuatan dan penngunaannya.
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
ES2241042T3 (es) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
WO1998055495A2 (en) 1997-06-06 1998-12-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
ES2298316T3 (es) 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
WO1999040934A1 (en) 1998-02-12 1999-08-19 Immune Complex, Corporation Strategically modified hepatitis b core proteins and their derivatives
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
ATE356630T1 (de) 1998-04-03 2007-04-15 Univ Iowa Res Found Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
ES2234180T3 (es) * 1998-04-09 2005-06-16 Idexx Laboratories, Inc. Proteinas de fijacion especifica para el tratamiento de la alergia canina.
IL138000A0 (en) 1998-04-09 2001-10-31 Smithkline Beecham Biolog Adjuvant compositions
US6734287B1 (en) * 1998-04-09 2004-05-11 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
ES2233101T3 (es) 1998-09-03 2005-06-01 Chiron Corp Dosis unitaria de fgf-2 angiogenicamente efectiva y su utilizacion.
ES2188003T3 (es) 1998-09-18 2003-06-16 Pentapharm Ag Inhibidores de la uroquinasa.
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
ATE314095T1 (de) 1998-10-21 2006-01-15 Us Health Virusähnliche partikel zur induktion von autoantikörpern
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
CA2349505A1 (en) 1998-11-05 2000-05-11 Powderject Vaccines, Inc. Nucleic acid constructs for genetic immunization
NZ512456A (en) 1998-11-30 2003-10-31 Cytos Biotechnology Ag Ordered molecular presentation of antigens
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
WO2000048630A1 (en) 1999-02-17 2000-08-24 Csl Limited Immunogenic complexes and methods relating thereto
CN1520423A (zh) * 1999-02-25 2004-08-11 ʷ��˿�������ȳ�ķ���޹�˾ 来源于IgE的Cε3或Cε4区的抗原决定基或拟表位,其拮抗物,及其治疗用途
ES2275499T3 (es) 1999-03-19 2007-06-16 Glaxosmithkline Biologicals S.A. Vacuna contra streptococcus pneumoniae.
AU757334B2 (en) * 1999-03-30 2003-02-13 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
DE60014076T2 (de) 1999-04-19 2005-10-13 Glaxosmithkline Biologicals S.A. Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid
KR20020048942A (ko) 1999-09-24 2002-06-24 장 스테판느 폴리옥시에틸렌 알킬 에테르 또는 에스테르 및 하나이상의 비이온성 계면활성제를 포함하는 애쥬번트
CZ20021043A3 (cs) 1999-09-24 2002-08-14 Smithkline Beecham Biologicals S. A. Pouľití kombinace polyoxyethylensorbitanového esteru a oktoxynolu pro výrobu pomocného prostředku
EP1220684B2 (en) 1999-09-27 2010-07-14 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
MXPA02009895A (es) 2000-04-07 2004-09-06 Univ Leeds Innovations Ltd Proteinas de fusion de antigeno de nucleo de hepatitis b.
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
ATE320493T1 (de) 2000-06-22 2006-04-15 Ucb Pharma Ltd Modifizierung des hepatitis b kernantigens
EP1304947A1 (en) 2000-07-15 2003-05-02 Lighthouse Display International Limited Shelf edge display fittings
AUPQ912000A0 (en) 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
GB0026334D0 (en) * 2000-10-27 2000-12-13 Smithkline Beecham Biolog Vaccine
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
AU2002339224B2 (en) 2001-09-14 2008-10-09 Kuros Us Llc Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
JP4360906B2 (ja) 2001-09-14 2009-11-11 サイトス バイオテクノロジー アーゲー ウィルス様粒子によって誘導される免疫応答を高めるための、抗原提示細胞のインビボでの活性化
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
AU2003213168A1 (en) 2002-02-21 2003-12-19 Apovia, Inc. IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE
US20040176283A1 (en) * 2002-04-01 2004-09-09 Robinson John A. Methods and compositions for the design of synthetic vaccines
GB0209878D0 (en) 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
CU22983A1 (es) * 2002-05-08 2004-09-09 Inst Finlay Composición vacunal contra las alergias y método para su obtención y empleo en el tratamiento de las mismas
EP2351770A1 (en) 2002-07-17 2011-08-03 Cytos Biotechnology AG Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
EP1572234B1 (en) 2002-12-10 2012-02-22 Sanofi Pasteur Biologics Co. STABILIZED IMMUNOGENIC HBc CHIMER PARTICLES
EP1605972A2 (en) * 2003-03-26 2005-12-21 Cytos Biotechnology AG Hiv-peptide-carrier-conjugates
EP1718669A4 (en) 2004-02-02 2007-10-10 Tanox Inc IDENTIFICATION OF NEW IGE EPITOPES
CA2574090A1 (en) 2004-07-18 2006-12-21 Coley Pharmaceutical Group, Ltd. Methods and compositions for inducing innate immune responses
KR100958505B1 (ko) 2004-07-18 2010-05-17 씨에스엘 리미티드 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기위한 올리고뉴클레오티드 제제
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
EP1924279A2 (en) * 2005-09-07 2008-05-28 The Secretary of State for Defence Adjuvanted vaccine
US20080045473A1 (en) 2006-02-15 2008-02-21 Coley Pharmaceutical Gmbh Compositions and methods for oligonucleotide formulations
US20080166785A1 (en) 2006-08-16 2008-07-10 Monica Sala-Schaeffer Polynucleotides allowing the expression and secretion of recombinant HBsAg virus-like particles containing a foreign peptide, their production and use
UY30994A1 (es) 2007-04-02 2008-11-28 Amgen Fremont Inc Anticuerpos anti-ige
US20100203083A1 (en) * 2007-05-31 2010-08-12 Medigene Ag Mutated structural protein of a parvovirus
US9501570B2 (en) 2014-07-14 2016-11-22 Verizon Patent And Licensing Inc. Dynamic routing system
US9719791B2 (en) 2014-12-10 2017-08-01 Mapquest, Inc. Computerized systems and methods for providing travel information and/or content to users
CN109640757B (zh) 2016-06-23 2021-02-09 睿谱有限公司 用于在饮料上打印的装置与方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0263655A2 (en) * 1986-10-03 1988-04-13 Dainippon Pharmaceutical Co., Ltd. Novel peptides having antiallergic activity
WO1999067293A1 (en) * 1998-06-20 1999-12-29 United Biomedical Inc. Peptide composition as immunogen for the treatment of allergy
US20030170229A1 (en) * 1999-02-25 2003-09-11 Smithkline Beecham Biologicals S.A. Vaccine
EP1195161A2 (en) * 2000-08-30 2002-04-10 Pfizer Products Inc. Anti-IgE vaccines
US20060062782A1 (en) * 2000-08-30 2006-03-23 Morsey Mohamad A Anti-IgE vaccines
WO2004058799A2 (en) * 2002-12-20 2004-07-15 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of ige to a high affinity receptor

Also Published As

Publication number Publication date
HK1163511A1 (zh) 2012-09-14
IL213029A0 (en) 2011-07-31
CN102245198A (zh) 2011-11-16
JP5209800B2 (ja) 2013-06-12
KR20130032390A (ko) 2013-04-01
KR20110094134A (ko) 2011-08-19
JP2012255006A (ja) 2012-12-27
CA2744754A1 (en) 2010-06-17
JP2016164156A (ja) 2016-09-08
WO2010067286A2 (en) 2010-06-17
MX2011006077A (es) 2011-09-01
KR101634058B1 (ko) 2016-06-27
PE20142330A1 (es) 2015-01-14
TW201036632A (en) 2010-10-16
EP2865389A1 (en) 2015-04-29
NZ604186A (en) 2014-07-25
ZA201104072B (en) 2012-02-29
US20120294848A1 (en) 2012-11-22
KR20150056881A (ko) 2015-05-27
PE20110891A1 (es) 2011-12-23
US20140017239A1 (en) 2014-01-16
AR074505A1 (es) 2011-01-19
JP2012511322A (ja) 2012-05-24
JP2014012009A (ja) 2014-01-23
BRPI0922561A2 (pt) 2020-08-11
RU2495049C2 (ru) 2013-10-10
EP2376108B1 (en) 2017-02-22
WO2010067286A3 (en) 2010-08-05
AU2009325950A1 (en) 2010-06-17
CN102245198B (zh) 2016-08-17
TWI387463B (zh) 2013-03-01
ES2622562T3 (es) 2017-07-06
EP2376108A2 (en) 2011-10-19
KR101413844B1 (ko) 2014-06-30
NZ592977A (en) 2013-01-25
DK2376108T3 (en) 2017-04-24
US20100158933A1 (en) 2010-06-24
SG10201400388QA (en) 2014-05-29
KR101644221B1 (ko) 2016-07-29
US9216229B2 (en) 2015-12-22
SG186611A1 (en) 2013-01-30
RU2011121043A (ru) 2013-01-20
US8298547B2 (en) 2012-10-30
JP5367137B2 (ja) 2013-12-11
US8475801B2 (en) 2013-07-02
JP5964280B2 (ja) 2016-08-03
MX337723B (es) 2016-03-15
CO6561830A2 (es) 2012-11-15

Similar Documents

Publication Publication Date Title
AU2009325950B2 (en) IgE CH3 peptide vaccine
AU2010277254B2 (en) Antigenic tau peptides and uses thereof
CA2846746A1 (en) Pcsk9 vaccine
EP2575868A1 (en) Ige ch3 peptide vaccine
AU2013204233B2 (en) IgE CH3 peptide vaccine
AU2013273674A1 (en) PCSK9 vaccine
HK1163511B (zh) Ige ch3肽疫苗

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired